AI Verdict
RANI has stronger fundamentals based on our AI analysis.
RAPH vs RANI Fundamental Comparison
| Metric | RAPH | RANI |
|---|---|---|
| Revenue | N/A | $1.6M |
| Net Income | $-1.3M | $-29.7M |
| Net Margin | N/A | -1,817.1% |
| ROE | N/A | -89.9% |
| ROA | -2,413.2% | -50.6% |
| Current Ratio | 0.03x | 4.21x |
| Debt/Equity | N/A | 0.00x |
| EPS | $0.07 | $-0.45 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
RAPH vs RANI: Frequently Asked Questions
Is RAPH or RANI a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), RANI has stronger fundamentals. RAPH is rated STRONG SELL (90% confidence) while RANI is rated SELL (48% confidence). This is not investment advice.
How does RAPH compare to RANI fundamentally?
Raphael Pharmaceutical Inc. has ROE of N/A vs Rani Therapeutics Holdings, Inc.'s -89.9%. Net margins are N/A vs -1,817.1% respectively.
Which stock pays higher dividends, RAPH or RANI?
RAPH has a dividend yield of N/A or no dividend while RANI has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in RAPH or RANI for long term?
For long-term investing, consider that RAPH has STRONG SELL rating with 90% confidence, while RANI has SELL rating with 48% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about RAPH vs RANI?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For RAPH vs RANI, the AI consensus favors RANI based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.